A New Bug Using Old Tricks!
Identifying, treating, and preventing Candida auris, the invasive multi-drug resistant yeast associated with severe nosocomial infections, is a challenge facing more and more healthcare settings. With 90% of C. auris isolates resistant to fluconazole, and 40% resistant to at least two classes of antifungal agents, limited treatment options exist for patients colonized with C. auris, reported Snigdha Vallabhaneni, MD, MPH, of the CDC in Atlanta, and colleagues.

"From an infection control perspective, C. auris acts more like a multidrug-resistant, health care-associated bacteria than like a typical yeast. It is a new bug using old tricks mastered by some well-known, multidrug resistant organisms," they wrote.

Clinically, C. auris is linked with bloodstream infections and intra-abdominal infections, as well as endocarditis, surgical site infections, osteomyelitis, and endophthalmitis, the authors said. Specifically, they cited a study that found 5% of patients with C. auris skin colonization developed invasive blood stream infection within a year, and of those, 40% died within 30 days.

In the meantime, the authors said that rapid diagnostic tests and effective decolonization methods are "urgently needed," and also recommended "bolstering laboratory detection capacity, strengthening public health surveillance and improving infection control practices."

Source: https://www.medpagetoday.com/infectiousdisease/infectioncontrol/81290
Dr. S●●●●●●e C●●●●●●●y and 2 other likes this